{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:54:15Z","timestamp":1792518855646,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":3394,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["RO1-CA112567"],"award-info":[{"award-number":["RO1-CA112567"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["KG091020"],"award-info":[{"award-number":["KG091020"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA116199"],"award-info":[{"award-number":["P50 CA116199"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA 16672"],"award-info":[{"award-number":["P30-CA 16672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-08-1-0712"],"award-info":[{"award-number":["W81XWH-08-1-0712"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.2353\/ajpath.2010.090885","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T22:33:02Z","timestamp":1283466782000},"page":"1647-1656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":247,"title":["PTEN, PIK3CA, p-AKT, and p-p70S6K Status"],"prefix":"10.1016","volume":"177","author":[{"given":"Francisco J.","family":"Esteva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Santa-Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry S.","family":"Lanchbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul A.","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dihua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2353\/ajpath.2010.090885_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.2353\/ajpath.2010.090885_bib2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/90.17.1262","article-title":"Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk","volume":"90","author":"Rohan","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.2353\/ajpath.2010.090885_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","article-title":"ErbB receptors and signaling pathways in cancer","volume":"21","author":"Hynes","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.2353\/ajpath.2010.090885_bib4","first-page":"511S","article-title":"ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms","volume":"9","author":"Kurokawa","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib5","first-page":"243","article-title":"Trastuzumab: targeted therapy for the management of HER-2\/neu-overexpressing metastatic breast cancer","volume":"12","author":"Emens","year":"2005","journal-title":"Am J Ther"},{"key":"10.2353\/ajpath.2010.090885_bib6","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.2353\/ajpath.2010.090885_bib7","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.2353\/ajpath.2010.090885_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2002.07.058","article-title":"Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer","volume":"20","author":"Esteva","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.2353\/ajpath.2010.090885_bib10","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"10.2353\/ajpath.2010.090885_bib12","first-page":"4132","article-title":"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action","volume":"62","author":"Yakes","year":"2002","journal-title":"Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib13","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1517\/14656566.9.15.2583","article-title":"HER-2-positive metastatic breast cancer: trastuzumab and beyond","volume":"9","author":"Metro","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.2353\/ajpath.2010.090885_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2009.216","article-title":"Molecular predictors of response to trastuzumab and lapatinib in breast cancer","volume":"7","author":"Esteva","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.seminoncol.2003.08.011","article-title":"Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer","volume":"30","author":"Mills","year":"2003","journal-title":"Semin Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.2353\/ajpath.2010.090885_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ccr.2009.04.004","article-title":"PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2\/ErbB3 is not always enough","volume":"15","author":"Hynes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.2353\/ajpath.2010.090885_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-004-7715-1","article-title":"Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors","volume":"91","author":"Chan","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.2353\/ajpath.2010.090885_bib20","first-page":"M21","article-title":"The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling","volume":"1470","author":"Vazquez","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.2353\/ajpath.2010.090885_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","article-title":"The PIK3CA gene is mutated with high frequency in human breast cancers","volume":"3","author":"Bachman","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"10.2353\/ajpath.2010.090885_bib22","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma","volume":"65","author":"Saal","year":"2005","journal-title":"Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib23","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-06-1609","article-title":"PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer","volume":"13","author":"Perez-Tenorio","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib24","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"10.2353\/ajpath.2010.090885_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"key":"10.2353\/ajpath.2010.090885_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12032-008-9127-2","article-title":"Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy","volume":"26","author":"Yonemori","year":"2008","journal-title":"Med Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/annonc\/mdn681","article-title":"EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab","volume":"20","author":"Gori","year":"2009","journal-title":"Ann Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib29","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1158\/0008-5472.CAN-04-4559","article-title":"ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin\/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells","volume":"66","author":"Klos","year":"2006","journal-title":"Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.bjc.6603838","article-title":"Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer","volume":"97","author":"Zhou","year":"2007","journal-title":"Br J Cancer"},{"key":"10.2353\/ajpath.2010.090885_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2559.2008.03075.x","article-title":"Oestrogen receptor status of breast carcinoma: allred\/H score conversion table","volume":"53","author":"Shousha","year":"2008","journal-title":"Histopathology"},{"key":"10.2353\/ajpath.2010.090885_bib32","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib33","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1200\/JCO.2006.06.5599","article-title":"Measures of response: rECIST. WHO, and new alternatives","volume":"24","author":"Jaffe","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib34","first-page":"105","article-title":"Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies","volume":"1786","author":"Singer","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.2353\/ajpath.2010.090885_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ncponc1298","article-title":"Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer","volume":"6","author":"Mariani","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"10.2353\/ajpath.2010.090885_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.bjc.6602926","article-title":"PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer","volume":"94","author":"Fujita","year":"2006","journal-title":"Br J Cancer"},{"key":"10.2353\/ajpath.2010.090885_bib37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/modpathol.3880371","article-title":"Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer","volume":"14","author":"Depowski","year":"2001","journal-title":"Mod Pathol"},{"key":"10.2353\/ajpath.2010.090885_bib38","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1158\/0008-5472.CAN-06-2101","article-title":"Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers","volume":"67","author":"Xia","year":"2007","journal-title":"Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib39","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","article-title":"Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency","volume":"13","author":"Lu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.2353\/ajpath.2010.090885_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2009.04.012","article-title":"AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer","volume":"16","author":"Vasudevan","year":"2009","journal-title":"Cancer Cell"},{"key":"10.2353\/ajpath.2010.090885_bib41","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0002-9440(10)65227-3","article-title":"Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast","volume":"155","author":"Perren","year":"1999","journal-title":"Am J Pathol"},{"key":"10.2353\/ajpath.2010.090885_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-006-9295-8","article-title":"Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma","volume":"101","author":"Tokunaga","year":"2007","journal-title":"Breast Cancer Res Treat"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944010602180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944010602180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:47:45Z","timestamp":1762080465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944010602180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0002944010602180"],"URL":"https:\/\/doi.org\/10.2353\/ajpath.2010.090885","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PTEN, PIK3CA, p-AKT, and p-p70S6K Status","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.2353\/ajpath.2010.090885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}